Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817056) titled 'Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence' on Sept. 8.
Study Type: Observational
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
Breast Cancer
Hyperglycemia
Intervention:
Other: Risk-stratified hyperglycemia management strategy
Recruitment Status: Recruiting
Date of First Enrollment: April 1, 2026
Target Sample Size: 100
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07817056
Published by HT Digital Content Services with permission from Health Daily Digest....